MGLL and ovarian cancer: As mentioned above, the activity of MAGL (which releases FAs from lipid reservoirs) is enhanced in a number of primary tumours, and its inhibition by the drug JZL184 results in reduced pathogenicity in murine models of melanoma and ovarian cancer (Nomura et al., 2010).